RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Targeted drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested the drug zanubrutinib in 65 adults with a specific genetic form (CD79B mutant) of relapsed or refractory diffuse large B-cell lymphoma, an aggressive blood cancer. Participants took zanubrutinib capsules twice daily and were monitored for tumor response and side…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for tough lymphoma: drug cocktail shows promise
Disease control CompletedThis early-phase trial tested a new drug called ociperlimab combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had returned or stopped responding to treatment. The main goal was to check safety and find the right dose. Researchers also…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 26, 2026 17:06 UTC